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Abstract
Cardiovascular diseases (CVDs) such as ischemic heart disease (IHD), stroke, and 
peripheral artery disease (PAS) are the leading causes of mortality and morbidity around 
the world; about 30% of global deaths and 10% of global disease burden a year are due 
to CVDs. In this chapter, we will analyze the classic concepts of vascular remodeling, 
to later expand the concepts and physiopathological mechanisms of vascular inflamma-
tion. The role of immunomodulation from IL-6R alpha and the JAK/STAT3 intracellular 
cascade, will be proposed as an activator of vascular remodeling mechanisms. In addi-
tion, the role of new drugs such as LCZ696 and immunomodulators involved in the local 
inflammatory response will also be analyzed. The concept of remodeling and vascular 
inflammation, which a decade ago was only important at the level of basic research, step-
by-step has proven crucial in the appearance of atherosclerosis, called subclinical athero-
sclerosis. Even though much progress has been made in the treatment and discovery of 
pathophysiological mechanisms, it has not been possible to reduce of cardiovascular risk, 
this is perhaps, it the decade in which we can advance in this.
Keywords: vascular remodeling, vascular inflammation, LCZ696, insulin resistance, 
IL-6R alpha
1. Introduction
Cardiovascular diseases (CVDs) such as ischemic heart disease (IHD), stroke, and peripheral 
artery disease (PAS) are the leading causes of mortality and morbidity around the world; about 
30% of global deaths and 10% of global disease burden a year are due to CVDs [1, 2]. In the 
past three decades, these diseases have been increasing in underdeveloped and developing 
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countries. Although deaths from CVDs have declined in some developed countries with better 
healthcare interventions and systems and primary prevention, population growth and aging 
will drive up global CVDs in the coming decades [1, 2].
Vascular diseases, including atherosclerosis, media calcification, macrovascular expression of 
diabetes vascular disease, and microangiopathy, are very prevalent in these patients and are 
primary causes of death and disability in these individuals (see Figure 1) [3].
The nexus between microangiopathy and macroangiopathy is not yet fully explained, but 
it is much more important than a simple time line, although it could be said that microan-
giopathic pathology precedes macroangiopathy in 5–10 years in the natural history of the 
disease. Atherosclerosis occurs earlier in patients with diabetes, frequently with greater sever-
ity and a more diffuse distribution. Diabetes and metabolic syndrome are associated with 
vascular function abnormalities and ensuing morphological changes associated with vascular 
remodeling and atherosclerosis [4, 5].
One way to study vascular disease in diabetes mellitus is through experimental models in 
animals. One of them consists of feeding with carbohydrate-enriched diets to normal rats for 
induced metabolic syndrome [6, 7]. Fructose-fed rats (FFR) have been used to assess the patho-
physiological mechanisms involved in the development of this syndrome [8]. This model has 
proven to be very interesting, since it allows the study of vascular changes, associated with 
metabolic syndrome, without the effects produced by hypercholesterolemia.
Figure 1. The evolution of vascular disease, with atherosclerosis being the final stage and vascular remodeling of the 
vascular disease manifested as vascular insufficiency.
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2. Physiopathological changes
2.1. Role of insulin
Recent studies have suggested that insulin and Ang II share a cross talk at multiple levels 
(Figure 2). Insulin signaling is initiated by binding to its receptor. The insulin receptor is a 
heterotetrameric tyrosine kinase that after binding insulin undergoes a rapid tyrosine auto-
phosphorylation that activates the receptor kinase and allows transient interaction with IRS-1. 
Interaction of tyrosine-phosphorylated IRS-1 with PI3K results in PI3K activation and Akt 
phosphorylation, which stimulates translocation of Glut-4 to the sarcolemma to facilitate glu-
cose uptake and NO production in the endothelium to induce vasorelaxation [9].
Ang II has been shown to inhibit the insulin-PI3K signaling pathway in both vascular and 
skeletal muscle cells. Ang II inhibits downstream signaling, including Akt phosphorylation, 
Glut-4 translocation to the sarcolemma, and NO production in the endothelium [9].
In the vasculature, insulin stimulates two major signaling transduction cascades: PI3K and 
MAPK. Insulin stimulation of NO production through activation of the PI3K pathway leads 
to vasodilation and increased blood flow and subsequent augmentation of glucose disposal in 
skeletal muscle. Insulin also stimulates the MAPK pathway, which mediates cellular growth 
and migration as well as production of prothrombotic and profibrotic factors [10].
Figure 2. Insulin-Ang II relationship. Insulin signaling is initiated by binding to its receptor. The insulin receptor is a 
heterotetrameric tyrosine kinase that after binding insulin undergoes a rapid tyrosine autophosphorylation that activates 
the receptor kinase and allows transient interaction with IRS-1. Interaction of tyrosine-phosphorylated IRS-1 with PI3K 
results in PI3K activation and Akt phosphorylation, which stimulates translocation of Glut-4 to the sarcolemma to 
facilitate glucose uptake and NO production in the endothelium to induce vasorelaxation.
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Fasting plasma insulin levels in a normal insulin-sensitive individual are usually in the low-
picomolar range (50–150 pM). At this range, insulin constitutively stimulates the PI3K path-
way, which participates in the regulation of the metabolic effects of insulin and maintenance 
of vascular tone [11].
In insulin-resistant states, such as obesity and diabetes, fasting insulin levels may reach the 
nanomolar range and are often associated with activation of RAAS. In addition, insulin stimu-
lation of the PI3K pathway is selectively impaired.
2.2. Vascular changes
The spectrum of clinical and morphological changes that can be displayed has changed 
over time. One of the classifications we find is that proposed by author Gibbons [12]. These 
changes are shown predominantly in the relationship of light/medium vessel by changing the 
ratio of wall thickness by an increase in muscle mass or reorganization of the cellular and non-
cellular components. These changes increase vascular reactivity, which promotes increased 
peripheral resistance in diseases such as hypertension. Another form of vascular remodeling 
involves primarily changes in the dimensions of the light. In this example, the restructuring of 
the active components of cellular and noncellular vascular wall results in significant changes 
in the dimensions of the vascular lumen, with relatively small changes in wall thickness. The 
clinical examples of this type include remodeling associated with vascular dilation of blood 
flow which is consistently high, for example, an arteriovenous fistula or loss in cellularity and 
proteolysis of extracellular matrix, resulting in the formation of an aneurysm. By contrast, 
a mass reduction vascular caliber results from a long-term reduction in blood flow. In fact, 
rarefaction of the microcirculation is another form of vascular remodeling. The architecture 
of the vascular wall is also markedly changed in response to vascular injury. Neointima is 
formed as part of a repair response to injury involving thrombosis, migration, and prolifera-
tion of vascular cells, production of the matrix, and infiltration of inflammatory cells.
The term “remodeling” is limited to situations in which there is a change in the lumen of a vessel 
relaxed, measured under a standard intravascular pressure, and where changes in the charac-
teristics of the wall material (i.e., the wall stiffness) do not consider the change in the vascular 
lumen [13].
Chronic changes in hemodynamic forces produce structural alterations in the vascular wall, as 
stated above. Furthermore, hemodynamic changes are not the only production mechanisms 
of vascular remodeling [14], and the role of the inflammatory response and changes in matrix 
components have been suggested as mediators in this process of vascular adaptation [15].
To complete the above concept, the vascular wall remodeling is the result of changes in cellular 
and noncellular components, depending on the disease process causing the changes. Changes 
in growth and migration of VSMC, endothelial dysfunction, the inflammatory process, syn-
thesis, or degradation of extracellular matrix components may be present in this process.
2.3. Vascular remodeling and inflammation
The traditional view of atherosclerosis as a lipid storage disease crumbles in front of the 
large and growing evidence that inflammation contributes to the center at all stages of the 
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disease, from initial injury until the final stage of thrombotic complications that compromise 
the bloodstream. Researchers now appreciate that the mere narrowing of the arterial lumen 
does not necessarily presage myocardial infarction and that simply treating narrowed blood 
vessels does not prolong life. Although invasive procedures such as angioplasty and coronary 
bypass will remain necessary in some cases, we now understand that medical treatment and 
lifestyle modification (diet and physical activity) produce benefits that may result from reduc-
tions in the processes inflammatory [16].
2.4. Initiation of atherosclerosis
It has been shown that atherosclerosis is not only a disease of lipid deposition but also a 
complex interaction between resident cells, inflammatory cells, and extracellular matrix, asso-
ciated with a characteristic phenotypic change of macrophages to foam cells.
A key part of this interaction between the endothelium and the leukocytes is the vascular cell 
adhesion molecule-1 (VCAM-1). VCAM-1 binds to monocytes and T lymphocytes; these leu-
kocytes are found in early atherosclerotic plaques. The most important stimuli for the mem-
brane docking of this molecule are the nuclear factor kB (NF-kB) as well as the interleukin-1β 
(IL-1β) and the tumor necrosis factor (TNF-α) [10].
Cell adhesion molecules (CAM) are essential in the mediation of adhesion and transendothelial 
migration of leukocytes. In several murine models, the absence of CAM reduces atherogenesis 
[17]. We have demonstrated the presence of VCAM-1 in the endothelium in an experimental 
model of metabolic syndrome, in which the expression of this protein is familiar with the AT1 
receptor (AT1R) and the local inflammatory process. High levels of ICAM-1 are predictive of 
cardiac events and are also independent cardiovascular risk factors [18]. This relationship was 
examined by Pradhan et al. [19], who showed that men with and without prior ischemic heart 
disease, accelerated atherogenesis, are associated with elevated levels of ICAM-1.
VCAM-1 is expressed in endothelial cells at sites predisposed to plaque formation [20]. By 
contrast, ICAM-1 is expressed throughout the plate; VCAM-1 is detected only in areas of 
rupture. In addition, VCAM-1 levels have a consistent association with atherosclerosis; high 
levels of VCAM-1 in the transcardiac gradient correlate with endothelial dysfunction and the 
progression of coronary atherosclerosis [21].
3. Pharmacology on vascular remodeling
3.1. New drugs
LCZ696 is the first of a new class of drugs that simultaneously block angiotensin 1 recep-
tor blocker (ARB) and neprilysin or neutral endopeptidase protein (NEP); hence, they are 
referred to with the acronym ARNI [22].
This complex system results in multiple effects on the cardiovascular system. In the first 
instance, according to different experiments, LCZ696 can increase the half-life of BNP through 
the initiation of NEP, managing to increase natriuresis and vasodilation through activation 
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of the NPRA receptor. On the other hand, the blockade of AT1R can decrease fibrosis, induce 
vasodilation, reduce the retention of sodium and water, lower blood pressure, and other 
effects [23].
The most important clinical study that demonstrated the reduction of cardiovascular morbid-
ity and mortality in patients with heart failure was the PARADIGM-HF study, which showed 
a clear benefit in patients who were in the branch receiving LCZ696. However, studies in 
experimental animals and pathophysiological analyses are scarce. Thus, the precise mecha-
nism by which LCZ696 reduces cardiovascular mortality remains unclear. Some authors have 
proposed different hypotheses: (1) a sustained increase in natriuretic peptides by inhibition 
of NEP, (2) a direct hemodynamic effect that reduces stress on the left ventricular wall, (3) a 
reduction in arrhythmias and by a reduction in fibrosis or myocardial hypertrophy, and (4) 
an improvement of regional myocardial perfusion [4].
Previously, drug-intervention studies in this model have shown that some antihypertensive 
treatments, with candesartan, telmisartan, and losartan, not only lower blood pressure but 
also cause an improvement in redox balance and regression of structural changes in resistance 
arteries, although not a regeneration of the endothelium. In other words, reversing adverse 
effects associated with hypertension does not improve the normal structure and function of 
endothelial cells [8, 9].
Within the inflammatory cascades activated in this experimental model, we found that the 
determinant of the previously evidenced changes is that of the IL-6 receptor. Two different 
forms of IL-6 cell receptors have been described: an 80 kDa ligand-binding chain, known as 
IL-6R (IL-6Ra, CD126), and a 130 kDa signal transduction chain, gp130 (IL-6Rb, CD130). Gp130 
is present in many places and situations; in contrast, IL-6R shows a more limited expression 
pattern [24].
In a recent publication of our group, it can be concluded that LCZ696 can reverse the changes 
associated with vascular remodeling, even more important than just blocking AT1R. The 
proposed pathway to demonstrate this finding was through the inhibition of the intracellular 
cascade of STAT3/JAK in intimate relation with IL-6R alpha, thus demonstrating an intrinsic 
anti-inflammatory effect. In addition, from the inhibition of STAT3, LCZ696 managed to 
significantly increase the amount of EPC at the vascular level, thus mediating endothelial 
repair [25].
The physiopathological mechanisms proposed in our work are summarized in Figure 3. The 
dual blocking of NEP/AT1R by LCZ696 could reduce the expression and phosphorylation of 
STAT3 through JAK, either by blocking AT1R, reducing oxidative stress, or controlling systolic 
blood pressure.
The reduction of STAT3 produced a decrease in the inflammatory transcription factors in 
the nucleus and a release of hsCRP in the blood circulation, which produces an increasing 
docking of the alpha subunit of IL-6R toward the membrane. Through this pathway, vascu-
lar remodeling and LVH were reduced because part of the growth factors and migration of 
muscle cells depend on the activation of the inflammatory cascade.
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On the other hand, NEP and ACE2 probably induce the conversion of angiotensin II in differ-
ent intermediate metabolites, such as angiotensin 1-7 (Ang 1-7), which produces antagonistic 
effects to angiotensin II by MAS1R. The intracellular cascade of MAS1R, by MAPK/ERK, pro-
duces a fundamental effect, namely, the production of VEGF and its two receptors, VEGFR1 
and VEGFR2. From this mechanism, the endothelium could be repaired and/or replaced, 
favoring the maturation of circulating EPCs on resident EPCs at the endothelial level. MAS1R 
could be counter-regulated by IL-1ß [26–28].
In conclusion, we postulate that LCZ696, by MAS1R activation, is not only able to improve 
endothelial function but also able to repair the endothelium, and this probably allows for 
improved functionality of the entire cardiovascular system. In addition, LCZ696 could reduce 
the expression of hsCRP through reduction in the expression of STAT3, a sign also demon-
strated in different clinical studies such as JUPITER and CANTOS, which have allowed a 
great reduction in morbidity and mortality, revolutionizing modern cardiology. The anti-
inflammatory and angio-repairing effect of LCZ696 is probably reflected in an improvement 
in the survival of patients who receive a treatment regimen with this drug in studies such as 
PARADIGM-HF [29–31].
Figure 3. The phytopathological mechanisms proposed in our work are summarized in this image. The dual blocking 
of NEP/AT1R by LCZ696 could reduce the expression and phosphorylation of STAT3 through JAK, either by blocking 
AT1R, reducing oxidative stress, or controlling systolic blood pressure. The reduction of STAT3 produced a decrease in 
the inflammatory transcription factors in the nucleus and a release of hsCRP in the blood circulation, which produces 
an increasing docking of the alpha subunit of IL-6R toward the membrane. On the other hand, NEP and ACE2 probably 
induce the conversion of angiotensin II in different intermediate metabolites, such as angiotensin 1-7 (Ang 1-7), which 
produces antagonistic effects to angiotensin II by MAS1R. The intracellular cascade of MAS1R, by MAPK/ERK, produces 
a fundamental effect, namely, the production of VEGF and its two receptors: VEGFR1 and 2. From this mechanism, the 
endothelium could be repaired and/or replaced, favoring the maturation of circulating EPCs on resident EPCs at the 
endothelial level. MAS1R could be counter-regulated by IL-1ß.
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3.2. Gliptin on vascular inflammation
Renna et al. suggest that incretin system dysfunction, as happens in patients with diabetes 
mellitus or metabolic syndrome, allows activation of inflammatory response in different  levels. 
The consequence is the creation of a vascular microenvironment that is conducive to the cre-
ation, perpetuation, progression, and destabilization of vascular injury, with either a simple 
eutrophic mechanism of vascular remodeling or the generation of an atherosclerotic lesion [32].
Several mechanisms may underlie these results: (1) increase the circulating levels of GLP-1 
[33]. The cardiovascular actions of GLP-1 may occur either directly through the GLP-1 recep-
tor or through a GLP-1 receptor-independent effect of the degradation product of GLP-1 [38]; 
(2) DPP-IV also degrades GIP and potentially cytokines and certain chemokines (includ-
ing stromal-derived factor 1-α). Thus, other substrates of DPP-IV may be responsible for 
the improvement in endothelial function. Alternatively, DDP-IV inhibition might improve 
endothelial function by influencing insulin and glucose levels. Insulin causes vasodilation by 
increasing endothelial production of NO [34].
The improvement in endothelial function and oxidative stress could result in a decrease in 
activation of the inflammatory process.
Other authors have suggested that the DDP-IV inhibitors may have anti-inflammatory effects, 
such as reduced activation of TNF-alpha during macrophage activation [33, 35].
4. Conclusion
There is sufficient evidence to show that insulin resistance and hyperinsulinism produce sig-
nificant changes at the vascular level [7, 25, 32, 36, 37]. The proposed mechanisms are (1) the 
IGF-1 receptor, (2) through the coactivation between IG-1 and AT1R, (3) by activating nuclear 
transcription factors such as NF-KB or AP-1, (4) by dimerization of IL-6R, and (5) from the 
activation of oxidative cascades such as NADP (H) oxidase, peroxynitrites, or superoxide 
dismutase (SOD). However, the effects of hyperglycemia are more erratic: moderate hyper-
glycemia is sufficient to induce adverse structural changes in the mesenteric vasculature, but 
more severe hyperglycemia is essential to cause endothelial dysfunction.
It is more interesting that the blocking of these pathways has significant effects on the acti-
vation/deactivation of vascular remodeling, independent of the correction or not, of hyper-
insulinism or insulin resistance. This shows that intracellular cascades, in most of these 
mechanisms, have no feedback from insulin or glucose receptors.
On the other hand, it is likely that the vascular remodeling associated with insulin resistance, 
due to the stimulation of growth factors, from the pathways, is due to changes in vascular hemo-
dynamics or to the increase in peripheral resistances, as in the case of arterial hypertension.
The new drugs, which modify the inflammatory modulating response, such as tocilizumab 
(anti-IL-6R alpha) and canakinumab (anti-IL-1b), will be drugs that could further modify the car-
diovascular risk of these patients in the future, since it could modify the vascular inflammatory 
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microenvironment, preventing vascular modeling and the subsequent formation of atheromatous 
plaques. Another pharmacological group that has gained importance in recent years is LCZ696, 
which, as several clinical studies have shown, modifies the cardiovascular morbidity and mortal-
ity of one of the most frequent pathologies of clinical practice, heart failure. However, new studies 
show that it is capable of producing effects in vascular repair, increasing the CPE at the vascular 
level, and avoiding vascular remodeling, even in experimental models with insulin resistance.
The concept of remodeling and vascular inflammation, which a decade ago was only impor-
tant at the level of basic research, step-by-step has proven crucial in the appearance of ath-
erosclerosis, called subclinical atherosclerosis. Much progress has been made in the treatment 
and discovery of pathophysiological mechanisms, rest improve the studies of deterrence, and 
its correlation with the reduction of cardiovascular risk; this is, perhaps, the decade in which 
we can advance in this.
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